Events

Retiro De Equipo (Recall) de Device Recall ATN System

Según U.S. Food and Drug Administration, este evento ( retiro de equipo (recall) ) involucró a un dispositivo médico en United States que fue producido por Zimmer Biomet, Inc..

¿Qué es esto?

Una corrección al equipo o acción de retiro tomada por el fabricante para abordar un problema con un dispositivo médico. Los retiros (recalls) ocurren cuando un dispositivo médico está defectuoso, cuando puede poner en riesgo la salud, o cuando simultáneamente está defectuoso y puede poner en riesgo la salud.

Más información acerca de la data acá
  • Tipo de evento
    Recall
  • ID del evento
    79408
  • Clase de Riesgo del Evento
    Class 2
  • Número del evento
    Z-1234-2018
  • Fecha de inicio del evento
    2017-12-20
  • Fecha de publicación del evento
    2018-03-14
  • Estado del evento
    Open, Classified
  • País del evento
    United States
  • Fuente del evento
    USFDA
  • URL de la fuente del evento
    https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfres/res.cfm?id=162249
  • Notas / Alertas
    U.S. data is current through June 2018. All of the data comes from the U.S. Food and Drug Administration, except for the category Manufacturer Parent Company.
    The Parent Company was added by ICIJ.
    The parent company information is based on 2017 public records.
  • Notas adicionales en la data
    Rod, fixation, intramedullary and accessories - Product Code HSB
  • Causa
    Zimmer biomet is conducting a medical device recall for the ace trochanteric nail (atn) system after a device performance review (dpr) failed clinical analysis for survivorship pursuant to the acceptance criteria for the dpr protocol for the atn system.
  • Acción
    On December 22, 2017 an URGENT MEDICAL DEVICE RECALL letter was issued to customers with a complete list of products subject to recall and requesting that the customer review the notification and notify all affected personnel of the recall. If there is affected product at the facility it is requested that these units be quarantined and returned to a sales representative for return to the firm. Questions or concerns can be directed to 574-371-3071.

Device

Device Recall ATN System
  • Modelo / Serial
    903311060 903311065 903311070 903311075 903311080 903311085 903311090 903311095 903311100 903311105 903311110 903311115 903311120 903311125 903311130
  • Clasificación del producto
    Orthopedic Devices
  • Clase de dispositivo
    2
  • ¿Implante?
    Yes
  • Distribución
    USA (nationwide)
  • Descripción del producto
    ACE Trochanteric Nail System || ATN LAG SCREW 60MM STERILE || ATN LAG SCREW 65MM STERILE || ATN LAG SCREW 70MM STERILE || ATN LAG SCREW 75MM STERILE || ATN LAG SCREW 80MM STERILE || ATN LAG SCREW 85MM STERILE || ATN LAG SCREW 90MM STERILE || ATN LAG SCREW 95MM STERILE || ATN LAG SCREW 100MM STERILE || ATN LAG SCREW 105MM STERILE || ATN LAG SCREW 110MM STERILE || ATN LAG SCREW 115MM STERILE || ATN LAG SCREW 120MM STERILE || ATN LAG SCREW 125MM STERILE || ATN LAG SCREW 130MM STERILE || The Trochanteric Nail System is intended to treat stable and unstable proximal fractures of the femur including pertrochanteric fractures, intertrochanteric fractures, high subtrochanteric fractures and combinations of these fractures. The Trochanteric Long Nail System is additionally indicated to treat pertrochanteric fractures associated with shaft fractures, pathologic fractures in osteoporotic bone of the trochanteric and diaphyseal areas, long subtrochanteric fractures, ipsilateral femoral fractures, proximal or distal nonunions and malunions and revision procedures.
  • Manufacturer
    Zimmer Biomet, Inc.

Manufacturer

Zimmer Biomet, Inc.
  • Dirección del fabricante
    Zimmer Biomet, Inc., 56 E Bell Dr, Warsaw IN 46582-6989
  • Empresa matriz del fabricante (2017)
    Zimmer Biomet Holdings
  • Comentario del fabricante
    “The safety of patients has always been, and continues to be, Zimmer Biomet’s top priority and it is our honor to be a leader in this industry for the past 90 years,” Zimmer Biomet told ICIJ in a statement. “We adhere to strict regulatory standards, and work closely with the FDA and all applicable regulatory agencies in each of our regions as part of our commitment to operating a first-rate quality management system across our global manufacturing network. The company added that it is focused on staying at the forefront of innovation and doing right by the millions of patients who rely on the company’s products.
  • Source
    USFDA